Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC89HI)

Drug Name

NM-9308 Drug Info

Synonyms

Bikaciomab; Bikaciomab (AMD), NovelMed Therapeutics; Complement factor B inhibitor (age related maculardegeneration), NovelMed Therapeutics; Anti-factor B monoclonal antibody (age related macular degenration), NovelMed Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Age-related macular degeneration	9B75.0	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMC89HI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement factor B (CFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Iptacopan	DM9EZM0	Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[2]
LPN023	DM7BN5W	IgA nephropathy	MF8Y	Phase 2	[3]
RG6299	DMVJL8W	Geographic atrophy	9B75	Phase 2	[4]
SAR443809	DMSUQTW	Discovery agent	N.A.	Phase 1	[5]
CAB-2	DMQ4HUA	Coronary artery disease	BA80	Discontinued in Phase 1	[6]
TA-106	DME2PFQ	Asthma	CA23	Investigative	[1]
PMID19743866C51	DMTX0ZJ	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement factor B (CFB)	TTA0P7K	CFAB_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339).
2	Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.
3	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166.
4	Clinical pipeline report, company report or official report of Roche
5	Clinical pipeline report, company report or official report of Sanofi
6	A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation. 2002 Mar;9(2):125-34.
7	Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem. 2009 Oct 8;52(19):6042-52.